Uterine cervical carcinosarcoma with heterologous mesenchymal ...

Collect this paper and discover other ones on Labmeeting. Learn more.
- Hide Abstract
INTRODUCTION: Carcinosarcomas of the uterine cervix are very rare. Most of them have a homologous mesenchymal component, and cervical carcinosarcomas with a heterologous mesenchymal component are limited to nine cases. CASE REPORT: A 61-year-old Japanese woman was admitted to the hospital for treatment of a ureteral stone. Imaging studies detected an indistinct cervical mass. A histopathological diagnosis of the cervical biopsy was a carcinosarcoma. A total abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy was carried out upon a diagnosis of stage Ib1 cervical carcinosarcoma. Microscopically, the cervical mass revealed a carcinosarcoma consisting of endometrioid adenocarcinoma and chondrosarcoma. Immunohistochemically, p53 was positive in the epithelial and mesenchymal components. Postoperatively, the patient underwent radiation and chemotherapy. She is alive with no evidence of recurrence 5 years and 10 months after the operation. CONCLUSION: We suppose that the similar proportion of p53 overexpression in both the epithelial and mesenchymal components may be one of the findings explaining the histogenesis of this tumor by combination theory.
Archives of gynecology and obstetrics 280(5):839-43, 2009 NovWho cited this? | PubMed ID: 19263060 | Fulltext


+ Click Here for Related Papers


Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.


Got a question?
The Labmeeting Network
has the answer.
Ask scientists at top universities like Harvard, Stanford, and MIT for their expert opinion!